{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:25:57Z","timestamp":1761488757617},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T00:00:00Z","timestamp":1315267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> Blood donor screening reduces the infectious hazards related to blood transfusion, but the range of agents to be screened for is debatable. In 1993, the screening of all blood donations for Human T\u2010Cell Lymphotropic virus (HTLV) was introduced in the Netherlands. We analysed the outcome and costs of HTLV donor screening.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> For the years 2001\u20132010, the number of HTLV infections among new and regular donors was used to estimate the prevented number of HTLV\u2010infected donors in the donor pool and the amount of morbidity prevented among recipients.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Human T\u2010Cell Lymphotropic virus screening in the Netherlands detects per year on average 1\u00b74 infected new donors and 0\u00b75 infected regular donors. The prevalence among new donors is 30 times higher than the incidence among regular donors. Without HTLV screening, 14 HTLV\u2010infected donors would be donating blood, causing 0\u00b78 to 0\u00b7007 cases of HTLV disease per year.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The lack of accurate estimators for infectivity and pathogenicity hampers the estimation of morbidity and mortality that HTLV\u2010infected transfusions would cause. Leucodepletion may be as effective as HTLV donor screening; its effect on HTLV transmission should be studied.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2011.01538.x","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T10:26:09Z","timestamp":1315304769000},"page":"198-203","source":"Crossref","is-referenced-by-count":18,"title":["The outcome of donor screening for Human T\u2010Cell Lymphotropic Virus infection in the Netherlands"],"prefix":"10.1111","volume":"102","author":[{"given":"F. J.","family":"Prinsze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L.","family":"Zaaijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208968"},{"key":"e_1_2_6_3_2","first-page":"144","article-title":"The epidemiology and disease outcomes of human T\u2010lymphotropic virus type II","volume":"6","author":"Roucoux DF","year":"2004","journal-title":"AIDS Rev"},{"issue":"1","key":"e_1_2_6_4_2","first-page":"S157","article-title":"Transmission of adult T\u2010cell leukaemia virus (HTLV\u2010I) through blood transfusion and its prevention","volume":"2","author":"Okochi K","year":"1986","journal-title":"AIDS Res"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2008.01136.x"},{"key":"e_1_2_6_6_2","first-page":"472","article-title":"HTLV\u2010I virus in Europeans: the continuous spread. A meta\u2010analysis","volume":"35","author":"Mayer V","year":"1991","journal-title":"Acta Virol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1984.tb00083.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7142.1417"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2567"},{"key":"e_1_2_6_10_2","first-page":"2541","article-title":"[The prevalence of human T\u2010lymphotropic virus type I among Dutch blood donors]","volume":"137","author":"Zaaijer HL","year":"1993","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_11_2","first-page":"1571","article-title":"[Infection with T\u2010lymphotropic virus in Dutch blood donors, 1993\u20131996]","volume":"141","author":"Zaaijer HL","year":"1997","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.8.2082.2082"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.2.677"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2004.00629.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002083220607"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/archinte.1991.00400100115019","article-title":"Transmission of human T\u2010lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). The American Red Cross HTLV\u2010I\/II Collaborative Study Group","volume":"151","author":"Sullivan MT","year":"1991","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910510609"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01312.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01881.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70081-6"},{"key":"e_1_2_6_21_2","volume-title":"Amsterdam, the Netherlands. Sanquin Blood Supply Foundation","author":"Sanquin Blood Foundation. [Faces of 2008. Annual Report]","year":"2009"},{"key":"e_1_2_6_22_2","volume-title":"Threshold Values for Intervention Cost Effectiveness by Region","author":"World Health Organization","year":"2000"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2008.09.001"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00198.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00932.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00788.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39101145.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.1.206"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00816.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33793325054.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33193142303.x"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2011.01538.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2011.01538.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T07:27:29Z","timestamp":1697614049000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2011.01538.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1423-0410.2011.01538.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2011.01538.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,6]]}}}